Table 3. Outcome in the CORAL study23 and NCIC CTG LY.12 study27,28.
| N | ORR (%) | CR (+ CRu) | PR (%) | PBSC mobilization failure (%) | HDT/ ASCT rate (%) | EFS (3-year) |
OS (3- year) |
||
|---|---|---|---|---|---|---|---|---|---|
| CORAL | R-ICE | 197 | 125 (63) | 72 (36) | 53 (27) | 20 (10) | 101 (51) | 26% | 47% |
| R-DHAP | 191 | 120 (63) | 75 (40) | 45 (24) | 15 (8) | 105 (55) | 35% | 51% | |
| p = 0.6 | p = 0.4 | ||||||||
| NCIC LY.12 | R-GDP | 220 | 103 (47) | 32/252 (13) | 118 (54) | 27% (4-year) | 41% (4-year) | ||
| (DLBCL subset) | R-DHAP | 209 | 92 (44) | 106 (51) |
ORR, overall response rate; CR, complete response; CRu, complete remission uncertain; PR, partial response; PBSC, peripheral blood stem cell; ASCT, autologous stem cell support/transplantation; EFS, event-free survival; OS, overall survival; R-ICE, rituximab, ifosfamide, calboplatin, and etoposide; R-DHAP, rituximab, dexamethazone, high-dose cytarabine, and cisplatin; R-GDP, rituximab, gemcitabine, dexamethazone, and cisplatin